1. Adelaide Research & Scholarship

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 13 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2022RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia.Shanmuganathan, N.; Wadham, C.; Thomson, D.; Shahrin, N.H.; Vignaud, C.; Obourn, V.; Chaturvedi, S.; Yang, F.; Feng, J.; Saunders, V.; Kok, C.H.; Yeung, D.; King, R.M.; Kenyon, R.R.; Lin, M.; Wang, P.; Scott, H.; Hughes, T.; Schreiber, A.W.; Branford, S.
2013Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cellsWhite, D.; Eadie, L.; Saunders, V.; Hiwase, D.; Hughes, T.
2010Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapyHiwase, D.; White, D.; Zrim, S.; Saunders, V.; Vaz de Melo, J.; Hughes, T.
2010The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cellsEngler, J.; Frede, A.; Saunders, V.; Zannettino, A.; White, D.; Hughes, T.
2005In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de-novo CML.White, D.; Saunders, V.; Lyons, A.; Branford, S.; Grigg, A.; To, L.; Hughes, T.
2006OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinibWhite, D.; Saunders, V.; Dang, P.; Engler, J.; Zannettino, A.; Cambareri, A.; Quinn, S.; Manley, P.; Hughes, T.
2007Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activityWhite, D.; Saunders, V.; Dang, P.; Engler, J.; Venables, A.; Zrim, S.; Zannettino, A.; Lynch, K.; Manley, P.; Hughes, T.
2007Imatinib increases the intracellular concentration of nilotinib which may explain the observed synergy between these drugsWhite, D.; Saunders, V.; Quinn, S.; Manley, P.; Hughes, T.
2010Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with ImatinibWhite, D.; Dang, P.; Engler, J.; Frede, A.; Osborn, M.; Saunders, V.; Manley, P.; Zrim, S.; Hughes, T.
2007Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemiaWhite, D.; Saunders, V.; Grigg, A.; Arthur, C.; Filshie, R.; Leahy, M.; Lynch, K.; To, L.; Hughes, T.

Discover